Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aditya Tedjaseputra

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Internal Medicine Journal|July 2, 2020
Excellent outcomes of transformed lymphomas in the rituximab era without autologous stem cell transplantation: an Australian single-centre experienceAditya Tedjaseputra, Michael Gilbertson, Michael Low, et al.
Ejhaem|August 21, 2025
Dynamic Profiling of Cell Free Tumour DNA in Aggressive B-Cell Lymphoma From Diagnosis to Transformation at RelapseMark Waltham, Jonathan Wong, Galina Polekhina, et al.
Pathology|April 5, 2024
Day-21 bone marrow findings incorrectly designate residual leukaemia in FLT3-mutated acute myeloid leukaemia treated with intensive induction plus midostaurin: a morphology-focused studyAditya Tedjaseputra, Sukanya Roy, Kay Htun, et al.
Leukemia & Lymphoma|June 21, 2022
Hyperleukocytosis associated with delayed presentation among patients with acute leukemia during the COVID-19 pandemicAditya Tedjaseputra, James A Kuzich, Nisha Thiagarajah, et al.
Blood Advances|September 30, 2025
Safety and efficacy of combining midostaurin and gemtuzumab ozogamicin with induction chemotherapy in FLT3-mutated AMLNigel Russell, Jad Othman, Oliver Cumming, et al.
Internal Medicine Journal|March 7, 2025
Ratifying the efficacy and safety of intensive induction chemotherapy for acute myeloid leukaemia by the Australasian Leukaemia & Lymphoma Group consensus approachAditya Tedjaseputra, Amanda Tey, Anastasios Nalpantidis, et al.
Blood Advances|September 23, 2021
Clinical impact of NPM1-mutant molecular persistence after chemotherapy for acute myeloid leukemiaIng S Tiong, Richard Dillon, Adam Ivey, et al.
Blood Advances|September 8, 2022
Characteristics and outcomes of patients with acute promyelocytic leukemia and extreme hyperleukocytosis at presentationHarry J Iland, Nigel Russell, Richard Dillon, et al.
Vox Sanguinis|March 25, 2025
International Forum on the Use of Irradiated Blood in Patients With Haematological Malignancy: ResponsesXiao-Yin Zhang, Michael Murphy, Graham P Collins, et al.
Vox Sanguinis|March 25, 2025
International Forum on the Use of Irradiated Blood in Patients With Haematological Malignancy: SummaryXiao-Yin Zhang, Michael Murphy, Graham P Collins, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Internal Medicine Journal|July 2, 2020
Excellent outcomes of transformed lymphomas in the rituximab era without autologous stem cell transplantation: an Australian single-centre experienceAditya Tedjaseputra, Michael Gilbertson, Michael Low, et al.
Ejhaem|August 21, 2025
Dynamic Profiling of Cell Free Tumour DNA in Aggressive B-Cell Lymphoma From Diagnosis to Transformation at RelapseMark Waltham, Jonathan Wong, Galina Polekhina, et al.
Pathology|April 5, 2024
Day-21 bone marrow findings incorrectly designate residual leukaemia in FLT3-mutated acute myeloid leukaemia treated with intensive induction plus midostaurin: a morphology-focused studyAditya Tedjaseputra, Sukanya Roy, Kay Htun, et al.
Leukemia & Lymphoma|June 21, 2022
Hyperleukocytosis associated with delayed presentation among patients with acute leukemia during the COVID-19 pandemicAditya Tedjaseputra, James A Kuzich, Nisha Thiagarajah, et al.
Blood Advances|September 30, 2025
Safety and efficacy of combining midostaurin and gemtuzumab ozogamicin with induction chemotherapy in FLT3-mutated AMLNigel Russell, Jad Othman, Oliver Cumming, et al.
Internal Medicine Journal|March 7, 2025
Ratifying the efficacy and safety of intensive induction chemotherapy for acute myeloid leukaemia by the Australasian Leukaemia & Lymphoma Group consensus approachAditya Tedjaseputra, Amanda Tey, Anastasios Nalpantidis, et al.
Blood Advances|September 23, 2021
Clinical impact of NPM1-mutant molecular persistence after chemotherapy for acute myeloid leukemiaIng S Tiong, Richard Dillon, Adam Ivey, et al.
Blood Advances|September 8, 2022
Characteristics and outcomes of patients with acute promyelocytic leukemia and extreme hyperleukocytosis at presentationHarry J Iland, Nigel Russell, Richard Dillon, et al.
Vox Sanguinis|March 25, 2025
International Forum on the Use of Irradiated Blood in Patients With Haematological Malignancy: ResponsesXiao-Yin Zhang, Michael Murphy, Graham P Collins, et al.
Vox Sanguinis|March 25, 2025
International Forum on the Use of Irradiated Blood in Patients With Haematological Malignancy: SummaryXiao-Yin Zhang, Michael Murphy, Graham P Collins, et al.
Pageof 3